Skip to main content
. 2022 Mar 9;13:857014. doi: 10.3389/fimmu.2022.857014

Table 6.

Approved/investigational drugs targeting hub common susceptibility genes.

Drug Target gene Effect
Glatiramer acetate HLA-DRB1 Immunomodulator
Daclizumab IL2RA Anti-CD25(IL-2) antibody
Filgotinib JAK1, TYK2 JAK inhibitor
Tofacitinib JAK1, TYK2 JAK inhibitor